Current Board Term Ends 2026-07-31 

Mrs. Bouchard has 20 years of experience, including 15 years in global regulatory affairs. She has been involved in the preparation of numerous applications and submissions, including INDs/CTAs to regulatory agencies and ethics committees, marketing applications (such as NDAs/BLAs/NDSs/MAAs), as well as pediatric plans. She has also been involved in and supported many types of meetings with regulatory agencies, such as pre-IND/CTA, FDA Types B and C, Scientific Advice, pre-NDS/MAA, FDA Advisory Board. 

She has experience in various therapeutic indications, mainly endocrinology and metabolism, hematology, immunology, neurology, respiratory, women’s health and psychiatry. At PRA Health Sciences, she leads a team of forty regulatory affairs professionals located in North, Central and South America.

Prior to joining PRA in 2013, she acted as a Regulatory Project Manager in a pharmaceutical company for a few years, after evolving in various quality assurance and regulatory roles in a Montreal-based biotechnology for thirteen years. Mrs. Bouchard is a passionate leader, willing to share and learn from each other's experience and expertise. She would be grateful to have the opportunity to serve CAPRA and support its growth, as the regulatory affairs field expands and evolves.

Current Board Term Ends 2025-07-31

Samar began her career in basic research in private and hospital settings, before transitioning to Regulatory Affairs. Currently, Samar is the Director of Regulatory Affairs at Boehringer-Ingelheim (Canada) Ltd., a global family owned Pharmaceutical Company. Samar’s proficiency includes over 29 years of experience in progressive roles in the Pharmaceutical Industry, with more than 22 years of proven strategic leadership and people management skills, motivating various teams in different functions to deliver high quality results in line with business priorities.

She graduated from the University of Western Ontario with a Master of Science degree in Molecular Biology, and most recently completed her Executive Master of Business Administration degree from the Ivey Business School in London, Ontario, Canada.

Current Board Term Ends 2025-07-31 

Danny has over 20 years of experience in developing regulatory strategies, leading registration and supporting launches of pharmaceuticals and biologics in Canada and international markets at Cato Research, Shire, Avir Pharma / Laboratoire Riva and JAMP Pharma, where he is currently heading the regulatory, pharmacovigilance and medical information teams. Danny is also responsible for the Regulatory Affairs option of the Masters Program in Drug Development at Université de Montréal. Serving on the CAPRA Board of Directors for the past 3 years (as Corporate Secretary and now Treasurer), Danny volunteers on the CAPRA Symposium Committee since 2003 and has been contributing author for the RAPS Fundamentals of Canadian Regulatory Affairs, Danny holds an M.Sc. in Drug Development (Regulatory Affairs), an MBA and is RAC-certified.

Current Board Term Ends 2026-07-31

Sandra Ireland is an accomplished and highly driven Regulatory Affairs and Quality Assurance executive with over 25 years of experience providing regulatory affairs, clinical affairs and quality strategies for small, medium and large domestic and international healthcare companies. She is a regulatory affairs certified (RAC) professional specializing in pharmaceutical drugs, medical devices, natural health products and cosmetics.

Sandra is the President of RaQa Consulting Inc. and Regulatory Solutions Inc. She is a part-time professor at Seneca College in the Pharmaceutical Regulatory Affairs and Quality Operations, as well as Cosmetic Science programs. Sandra is also involved with the Applied Research & Innovation projects at Seneca College.

She has been a member of CAPRA since 2001. Sandra received her B.Sc. in Biochemistry and Chemistry from the University of Western Ontario. She also holds a post-degree certification in Pharmaceutical Regulatory Affairs & Quality Operations from Seneca College, a Clinical Research Associate Diploma from the Michener Institute in Toronto, and an executive MBA from Athabasca University.

Current Board Term Ends 2025-07-31 

Bhavesh has 14 years of experience in Regulatory Affairs in Canada. His regulatory experience encompasses pharmaceutical drugs, natural health products, medical devices, cosmetics, and foods. Currently, he is the Board Lead at Education Day committee and working at Apotex Inc. Bhavesh has honor to wrote two chapters for the RAPS 2018 book, “Fundamentals of Canadian Pharmaceutical and Biologics Regulations”. He feels honored to co-design the Natural Health Product course at Seneca College, Toronto.

Current Board Term Ends 2025-07-31

Krista Coventry is the Senior Director of Clinical Affairs & Regulatory Strategy for Source Nutraceutical, Inc., a Canadian contract research organization. She is a regulatory affairs specialist with over 20 years of experience providing project management, regulatory strategies and market compliance solutions to industry clients, globally. Krista has expert knowledge of acts, regulations, policies and guidelines relating to natural health products, over-the-counter drugs, foods, cosmetics and medical devices; as well as clinical research requirements in these same fields. She has worked extensively with Canadian and U.S. regulatory frameworks to advise industry clients on various pre-market requirements (claims, labelling, safety prerequisites, clinical trials) in support of regulatory compliance initiatives in North American markets. She also specializes in strategic planning for health product commercialization, and has broad expertise in the critical evaluation of evidence-based clinical research in support of regulatory portfolios. Krista has held numerous distinguished volunteer affiliations with regulatory-based professional societies in North America and is a longstanding CAPRA volunteer. She has given 10 years of service to the CAPRA Board of Directors (2012-2023) and is the current Board Lead for Marketing.

Current Board Term Ends 2025-07-31

Queenia holds the position of Associate Director of Global Regulatory Intelligence & Policy at Apotex. She utilizes her years of pharmaceutical experience in Regulatory Operations, Regulatory Affairs, CMC & QA to support the CAPRA organization. As the Chair of the CAPRA Symposium Committee, she collaborates with Health Canada and industry colleagues regularly. She has led a dedicated symposium team to regularly offer CAPRA members numerous regulatory workshops to keep members up to date for over 15 years. She would like to thank all CAPRA members for their continued support.

Current Board Term Ends 2026-07-31 

Dr. Sherry Boodram is the CEO and Co-Founder of CannDelta Inc., a leading cannabis and psychedelics regulatory consulting company. She also serves as an Independent Board Advisor for a publicly traded Canadian cannabis extraction technology company. She has been a guest lecturer at local institutions including Osgoode Hall Law School, Seneca College, Humber College and the North American College of Pharmaceutical Technology to teach about domestic and international cannabis regulations.

Prior to founding CannDelta Inc., she spent several years at Health Canada as a Senior Regulatory Compliance Officer/Auditor where she was responsible for cannabis licensing application reviews and facility inspections under various cannabis regimes. She holds a Ph.D. in Chemistry from York University, a Hon. B.Sc. in Biological Chemistry from the University of Toronto, a Certificate in Cannabis Law and Regulation from Osgoode Hall Law School of York University, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College.

Sherry specializes in cannabis and psychedelics licensing submissions, international policy and regulation development, strategic mergers and acquisitions, due diligence inspections and audits, internal quality management systems, facility design, operational optimization, product registrations, and education. As the Chair of the CAPRA Webinar Committee, she aims to expand the knowledge base and existing regulatory network of the CAPRA community to build stronger relationships and provide increased professional and academic support.

Current Board Term Ends 2025-07-31

Audra has over 18 years of regulatory experience in the pharmaceutical industry. Her experience in regulatory affairs includes a broad range of activities with both small and large sized pharmaceutical companies, and includes activities from clinical development through marketed product/post-marketing activities. She has prepared scientific and regulatory documents for inclusion within Health Canada submissions, managing a number of New Drug Submissions through to approval. Her regulatory role has provided her the opportunity to interface directly with Health Canada for both pre-CTA and pre-NDS meetings.  In recent years, Audra has focused her career on supporting small to midsize companies through their clinical development programs.

 She obtained her BSc. in Biology from the University of Toronto and a Graduate Certificate in Regulatory Affairs from the Humber Institute of Technology and Advanced Learning.

Current Board Term Ends 2025-07-31

 Danielle Mason is a Senior Manager, Regulatory Affairs at TPIreg, Innomar Strategies Inc.  Danielle has been in the pharmaceutical industry for more than 20 years and has broad experience across various dosage types and specialties (solids, liquids, parenterals and biologics).   Danielle provides regulatory consulting support for both prescription drugs and medical devices.  In a secondary role as a Quality-Regulatory-Safety (QRS) Program Manager that includes several marketed products, Danielle serves as key Client liaison to ensure cross-functional activities are aligned and product activities comply with regulatory requirements.

 As part of her consulting role, Danielle has provided training to colleagues for new regulatory initiatives.  She has also provided project management training to recent graduates and working professionals who are seeking roles in regulatory affairs and the healthcare industry.  This experience sparked Danielle’s interest to lead the Student Relations Committee within CAPRA as she enjoys sharing her knowledge and experience to help others. Danielle graduated from University of Guelph in 2000 with a degree in Biological Engineering and earned the Project Management Professional certification in 2013.

Current Board Term Ends 2025-07-31

Mỹ has 20 years of drugs and some biologics regulatory affairs experience in the global pharmaceutical industry across various therapeutic areas.   Mỹ has also held various positions in quality assurance, spearheading inspections with Health Canada and CFIA (Canadian Food Inspection Agency) and in pharmacovigilance, and medical information bringing a broad perspective to her work in regulatory affairs.  In RA, she has experience in performing due diligence evaluations/submission gap analyses, establishing regulatory strategies, and overseeing various types of regulatory submissions including NDSs, SNDSs, CTAs, generic submissions and submissions for animal health products with the VDD and CFIA, etc.  Mỹ is skilled at providing technical guidance and expertise in the management of regulatory projects to optimize opportunities for successful outcomes.  Currently, she serves on the Board of Directors for CAPRA and is actively involved in DIA Canada’s Program Committee.  Outside of work, she a passionate leader mentoring/coaching students at McMaster University and serves on the Board of Directors for Canadian Parents for French, promoting bilingualism in Ontario for the next generation.  Mỹ obtained her M.B.A and B.Sc., from McMaster University.  

Current Board Term Ends 2026-07-31 

Marcos is a dedicated and accomplished professional with several years of experience in regulatory affairs within the life sciences and clinical research sectors. In his role as a senior Regulatory Affairs (RA) associate at Altasciences, a Contract Research Organization, Marcos has consistently showcased his strategic thinking and decision-making abilities, fostering a culture rooted in integrity and compliance.

Known for his excellent communication skills, Marcos effectively conveys complex regulatory requirements and strategies to a diverse range of stakeholders, including executive teams, regulatory bodies, and cross-functional teams. His collaborative approach encourages open dialogue, drives innovation, and ensures alignment with organizational goals. Marcos's proactive mindset and attention to detail enable him to navigate the ever-changing regulatory landscape, anticipating challenges and crafting effective solutions.

Marcos is also a skilled project manager, capable of leading multiple projects simultaneously while maintaining high standards of quality and efficiency. His ability to mentor and inspire his team fosters a supportive and productive work environment, enhancing overall team performance. Committed to continuous learning and professional development, Marcos stays up-to-date with industry trends and regulatory changes, bringing valuable insights to board discussions and decisions.

Beyond his professional expertise, Marcos is deeply committed to diversity and inclusion, recognizing the importance of varied perspectives in driving innovation and organizational success. His strategic vision and holistic approach to leadership contribute to the long-term growth and sustainability of the organization. As a board member, Marcos would bring a wealth of knowledge, experience, a collaborative spirit, and a wide network of connections in the RA industry, making him an asset to the board of directors.

Current Board Term Ends 2026-07-31 

Sadia is a distinguished Regulatory Affairs Professional with over 15 years of invaluable experience in the Pharmaceutical and Medical Devices industries. For the past 5 years, Sadia has served as the driving force behind Dr. Reddy’s Canada Regulatory Affairs Department, where she has led regulatory strategy development across diverse product classifications, product labeling, lifecycle management, and meticulous compliance with Health Canada’s stringent regulations.

Her tenure is marked by a track record of exemplary leadership and influential prowess, guiding global cross-functional teams to achieve ambitious corporate objectives. As the primary liaison with Health Canada, Sadia maintains a proactive stance through continuous regulatory intelligence, ensuring her organization remains ahead amidst the dynamic Canadian regulatory landscape.

Known for her collaborative spirit and proactive initiative, Sadia thrives in roles that require diverse responsibilities and a commitment to collective success. Her multifaceted skills and dedication position her as a pivotal collaborator within the CAPRA organization, ready to spearhead modernization initiatives and maintain a competitive edge over peer organizations.

Current Board Term Ends 2026-07-31 

Mia Spiegelman is the Vice President of Regulatory Affairs at Medtech Canada and holds a B.Sc. in Chemistry from York University as well as Certification in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College.

Throughout her 24 years in the industry, she has worked in various Medical Device, Pharmaceutical, Cosmetic and Consulting companies while holding various roles within the Quality and Regulatory fields.

Her current role responsibilities include developing, leading, implementing and managing the Regulatory Affairs strategic initiatives for Medtech Canada and its members in order to ensure that Canada has a globally competitive regulatory environment.

Current Board Term Ends 2026-07-31 

With over 20 years of regulatory experience in the pharmaceutical industry, I am eager to couple my expertise and my strong desire and commitment to professional education and development, to further CAPRA’s Mission of creating a professionally fulfilling and academically enriching environment.

After completing my Honours Bachelor of Science, I started my focus in Regulatory Affairs through the completion of the Regulatory Affairs and Quality Operations program at Seneca College. I then started my Regulatory Affairs career at a drug substance manufacturing site, followed by a position in the generic industry and then moved into the Brand pharmaceutical industry where I have been working for the past several years.

My career has provided me the privilege of leading, coaching and mentoring numerous young professionals, guiding them through the complexities of pharmaceutical sciences, the ever-evolving regulatory practices and their own development aspirations.

Additionally, my wide breadth of experience (mostly in prescription pharmaceuticals, but also experience with non-prescription (OTC) products, natural health products and cosmetics) and depth of experience (clinical and quality throughout all stages of the product lifecycle) allows me to bring a diverse perspective to the CAPRA Board.

Current Board Term Ends 2025-07-31 

Danny has over 20 years of experience in developing regulatory strategies, leading registration and supporting launches of pharmaceuticals and biologics in Canada and international markets at Cato Research, Shire, Avir Pharma / Laboratoire Riva and JAMP Pharma, where he is currently heading the regulatory, pharmacovigilance and medical information teams. Danny is also responsible for the Regulatory Affairs option of the Masters Program in Drug Development at Université de Montréal. Serving on the CAPRA Board of Directors for the past 3 years (as Corporate Secretary and now Treasurer), Danny volunteers on the CAPRA Symposium Committee since 2003 and has been contributing author for the RAPS Fundamentals of Canadian Regulatory Affairs, Danny holds an M.Sc. in Drug Development (Regulatory Affairs), an MBA and is RAC-certified.

Current Board Term Ends 2025-07-31 

Bhavesh has 14 years of experience in Regulatory Affairs in Canada. His regulatory experience encompasses pharmaceutical drugs, natural health products, medical devices, cosmetics, and foods. Currently, he is the Board Lead at Education Day committee and working at Apotex Inc. Bhavesh has honor to wrote two chapters for the RAPS 2018 book, “Fundamentals of Canadian Pharmaceutical and Biologics Regulations”. He feels honored to co-design the Natural Health Product course at Seneca College, Toronto.

Current Board Term Ends 2025-07-31

Krista Coventry is the Senior Director of Clinical Affairs & Regulatory Strategy for Source Nutraceutical, Inc., a Canadian contract research organization. She is a regulatory affairs specialist with over 20 years of experience providing project management, regulatory strategies and market compliance solutions to industry clients, globally. Krista has expert knowledge of acts, regulations, policies and guidelines relating to natural health products, over-the-counter drugs, foods, cosmetics and medical devices; as well as clinical research requirements in these same fields. She has worked extensively with Canadian and U.S. regulatory frameworks to advise industry clients on various pre-market requirements (claims, labelling, safety prerequisites, clinical trials) in support of regulatory compliance initiatives in North American markets. She also specializes in strategic planning for health product commercialization, and has broad expertise in the critical evaluation of evidence-based clinical research in support of regulatory portfolios. Krista has held numerous distinguished volunteer affiliations with regulatory-based professional societies in North America and is a longstanding CAPRA volunteer. She has given 10 years of service to the CAPRA Board of Directors (2012-2023) and is the current Board Lead for Marketing.

Current Board Term Ends 2025-07-31

Queenia holds the position of Associate Director of Global Regulatory Intelligence & Policy at Apotex. She utilizes her years of pharmaceutical experience in Regulatory Operations, Regulatory Affairs, CMC & QA to support the CAPRA organization. As the Chair of the CAPRA Symposium Committee, she collaborates with Health Canada and industry colleagues regularly. She has led a dedicated symposium team to regularly offer CAPRA members numerous regulatory workshops to keep members up to date for over 15 years. She would like to thank all CAPRA members for their continued support.

Current Board Term Ends 2026-07-31 

Dr. Sherry Boodram is the CEO and Co-Founder of CannDelta Inc., a leading cannabis and psychedelics regulatory consulting company. She also serves as an Independent Board Advisor for a publicly traded Canadian cannabis extraction technology company. She has been a guest lecturer at local institutions including Osgoode Hall Law School, Seneca College, Humber College and the North American College of Pharmaceutical Technology to teach about domestic and international cannabis regulations.

Prior to founding CannDelta Inc., she spent several years at Health Canada as a Senior Regulatory Compliance Officer/Auditor where she was responsible for cannabis licensing application reviews and facility inspections under various cannabis regimes. She holds a Ph.D. in Chemistry from York University, a Hon. B.Sc. in Biological Chemistry from the University of Toronto, a Certificate in Cannabis Law and Regulation from Osgoode Hall Law School of York University, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College.

Sherry specializes in cannabis and psychedelics licensing submissions, international policy and regulation development, strategic mergers and acquisitions, due diligence inspections and audits, internal quality management systems, facility design, operational optimization, product registrations, and education. As the Chair of the CAPRA Webinar Committee, she aims to expand the knowledge base and existing regulatory network of the CAPRA community to build stronger relationships and provide increased professional and academic support.

Current Board Term Ends 2025-07-31

Audra has over 18 years of regulatory experience in the pharmaceutical industry. Her experience in regulatory affairs includes a broad range of activities with both small and large sized pharmaceutical companies, and includes activities from clinical development through marketed product/post-marketing activities. She has prepared scientific and regulatory documents for inclusion within Health Canada submissions, managing a number of New Drug Submissions through to approval. Her regulatory role has provided her the opportunity to interface directly with Health Canada for both pre-CTA and pre-NDS meetings.  In recent years, Audra has focused her career on supporting small to midsize companies through their clinical development programs.

 She obtained her BSc. in Biology from the University of Toronto and a Graduate Certificate in Regulatory Affairs from the Humber Institute of Technology and Advanced Learning.

Current Board Term Ends 2025-07-31

 Danielle Mason is a Senior Manager, Regulatory Affairs at TPIreg, Innomar Strategies Inc.  Danielle has been in the pharmaceutical industry for more than 20 years and has broad experience across various dosage types and specialties (solids, liquids, parenterals and biologics).   Danielle provides regulatory consulting support for both prescription drugs and medical devices.  In a secondary role as a Quality-Regulatory-Safety (QRS) Program Manager that includes several marketed products, Danielle serves as key Client liaison to ensure cross-functional activities are aligned and product activities comply with regulatory requirements.

 As part of her consulting role, Danielle has provided training to colleagues for new regulatory initiatives.  She has also provided project management training to recent graduates and working professionals who are seeking roles in regulatory affairs and the healthcare industry.  This experience sparked Danielle’s interest to lead the Student Relations Committee within CAPRA as she enjoys sharing her knowledge and experience to help others. Danielle graduated from University of Guelph in 2000 with a degree in Biological Engineering and earned the Project Management Professional certification in 2013.

Current Board Term Ends 2026-07-31 

Marcos is a dedicated and accomplished professional with several years of experience in regulatory affairs within the life sciences and clinical research sectors. In his role as a senior Regulatory Affairs (RA) associate at Altasciences, a Contract Research Organization, Marcos has consistently showcased his strategic thinking and decision-making abilities, fostering a culture rooted in integrity and compliance.

Known for his excellent communication skills, Marcos effectively conveys complex regulatory requirements and strategies to a diverse range of stakeholders, including executive teams, regulatory bodies, and cross-functional teams. His collaborative approach encourages open dialogue, drives innovation, and ensures alignment with organizational goals. Marcos's proactive mindset and attention to detail enable him to navigate the ever-changing regulatory landscape, anticipating challenges and crafting effective solutions.

Marcos is also a skilled project manager, capable of leading multiple projects simultaneously while maintaining high standards of quality and efficiency. His ability to mentor and inspire his team fosters a supportive and productive work environment, enhancing overall team performance. Committed to continuous learning and professional development, Marcos stays up-to-date with industry trends and regulatory changes, bringing valuable insights to board discussions and decisions.

Beyond his professional expertise, Marcos is deeply committed to diversity and inclusion, recognizing the importance of varied perspectives in driving innovation and organizational success. His strategic vision and holistic approach to leadership contribute to the long-term growth and sustainability of the organization. As a board member, Marcos would bring a wealth of knowledge, experience, a collaborative spirit, and a wide network of connections in the RA industry, making him an asset to the board of directors.

Current Board Term Ends 2026-07-31 

Sadia is a distinguished Regulatory Affairs Professional with over 15 years of invaluable experience in the Pharmaceutical and Medical Devices industries. For the past 5 years, Sadia has served as the driving force behind Dr. Reddy’s Canada Regulatory Affairs Department, where she has led regulatory strategy development across diverse product classifications, product labeling, lifecycle management, and meticulous compliance with Health Canada’s stringent regulations.

Her tenure is marked by a track record of exemplary leadership and influential prowess, guiding global cross-functional teams to achieve ambitious corporate objectives. As the primary liaison with Health Canada, Sadia maintains a proactive stance through continuous regulatory intelligence, ensuring her organization remains ahead amidst the dynamic Canadian regulatory landscape.

Known for her collaborative spirit and proactive initiative, Sadia thrives in roles that require diverse responsibilities and a commitment to collective success. Her multifaceted skills and dedication position her as a pivotal collaborator within the CAPRA organization, ready to spearhead modernization initiatives and maintain a competitive edge over peer organizations.

Current Board Term Ends 2026-07-31 

Mia Spiegelman is the Vice President of Regulatory Affairs at Medtech Canada and holds a B.Sc. in Chemistry from York University as well as Certification in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College.

Throughout her 24 years in the industry, she has worked in various Medical Device, Pharmaceutical, Cosmetic and Consulting companies while holding various roles within the Quality and Regulatory fields.

Her current role responsibilities include developing, leading, implementing and managing the Regulatory Affairs strategic initiatives for Medtech Canada and its members in order to ensure that Canada has a globally competitive regulatory environment.